Trials & Filings

Alcobra Enrolls Last PI-ADHD Patient

Results expected by December 2013

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Alcobra Ltd. has successfully enrolled the 36th and final patient in a placebo-controlled Phase II study designed to compare the efficacy of varied dosage levels of MG01CI to treat and improve cognitive dysfunctions in adult subjects with Predominantly Inattentive Attention Deficit/Hyperactivity Disorder (PI-ADHD). The last patient visit is scheduled for November 26, 2013 and the data is expected to be announced during the week of December 16, 2013. The study is evaluating 700mg and 1,400mg dos...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters